Experiments confirmed that FPR1 and its ligand, annexin-1 (ANXA1), promoted stable interactions between dying cancer cells treated with anthracyclines and leukocytes, while FPR1 deficiency leads to the immune failure in approaching apoptotic cells leading to defective anticancer immune response and less efficient chemotherapy. The gene discussed is FPR1; the disease is cancer.